Recent studies have shown that treatment with OTS167 drastically suppresses the growth of various MELK-overexpressing cancer cell lines, including breast, lung, prostate, AML, gastric, kidney, and ovarian cancers [51–53, 58, 70]. Here, MELK is linked to cancer.